A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Inclusion Criteria: * History of CHF on individually optimized treatment with HF medications unless contraindicated or not tolerated, for at least 12 weeks prior to index hospitalization and in accordance with international guidelines. * Subjects admitted to the hospital with a primary diagnosis of decompensated HF including symptoms and signs of fluid overload requiring IV diuretic therapy in the Emergency room (ER) or any time between day 1-3 of hospital admission (index hospitalization). * Subjects on an average/usual total daily dose of loop diuretic ≥ 40 mg of furosemide or equivalent, within 4 weeks prior to index hospitalization. * At least one of the following 5 parameters any day between 3-7 of index hospitalization (screening period) * Natriuretic peptides Brain natriuretic peptide/N-terminal prohormone of brain natriuretic peptide (BNP/NT-proBNP): * Drop in BNP or NT-proBNP ≤ 30% from admission values (if measured during index hospitalization) or * BNP ≥ 500 pg/ml or NT-proBNP ≥ 1800 pg/ml at screening (day 3 to 7 of index hospitalization) * Body weight (BW) loss \<0.4 kg per 40 mg furosemide at day 4 of index hospitalization * Composite congestion score (CCS) ≥ 3 * Hypervolemic hyponatremia defined as serum sodium \< 136 mmol/l * In hospital worsening renal function defined as increased serum creatinine ≥ 0.3 mg/dl compared to index hospitalization admission values AND at least one the following * Jugular venous pressure (JVP) ≥ 10 cm on …